If you're sourcing compounded GLP-1s for your practice, you've likely encountered both 503A and 503B pharmacies — and you may not be entirely clear on which pathway applies to your clinic, or why it matters.

It matters a lot. The wrong supply pathway creates compliance exposure that can affect your DEA registration, your state medical license, and your patients' safety. Here's a clear breakdown.

503A pharmacies compound medications pursuant to valid patient-specific prescriptions from licensed prescribers. Every order is tied to an individual patient and a specific prescription. The pharmacy is regulated primarily by state pharmacy boards, with FDA oversight focused on safety and quality.

503B outsourcing facilities are FDA-registered facilities that can produce compounded drugs in bulk — without patient-specific prescriptions — for distribution to licensed healthcare facilities. They operate under stricter FDA oversight, including cGMP (Current Good Manufacturing Practice) standards, and are subject to FDA inspections.

The key distinction: 503A is prescription-driven. 503B is facility-driven.

503A is the appropriate supply pathway for most outpatient clinics, medical spas, and telehealth providers who are prescribing compounded GLP-1s to individual patients.

If your model looks like this, 503A is likely your pathway:

• You have a licensed prescriber (MD, DO, NP, PA) issuing patient-specific prescriptions
• You're treating individual patients for weight management, metabolic health, or related conditions
• You're operating as an outpatient clinic, med spa, or telehealth platform
• Your volume is patient-by-patient rather than bulk institutional supply

Under 503A, the pharmacy compounds the medication after receiving a valid prescription for a specific patient. The product is dispensed to that patient — not stocked in your office for general use.

503B outsourcing facilities serve a different market: licensed healthcare facilities that need to stock compounded medications for administration to patients without a prescription in hand at the time of ordering.

503B is typically the right pathway for:

• Hospitals and ambulatory surgical centers
• Clinics that administer medications in-office and need to maintain inventory
• High-volume providers who need bulk supply under cGMP standards
• Providers who need products not available through 503A channels

503B products come with stricter quality standards — cGMP manufacturing, FDA registration, and more rigorous testing requirements — which is why they can be distributed without patient-specific prescriptions.

The most common compliance mistake we see is a 503A pharmacy offering to ship bulk product for "office use" without patient-specific prescriptions. This is not legal under 503A. A 503A pharmacy cannot function as a 503B outsourcing facility — they are two distinct regulatory categories.

If a pharmacy is offering you bulk GLP-1 supply without requiring patient-specific prescriptions, and they are not an FDA-registered 503B outsourcing facility, you are participating in a transaction that falls outside the legal framework for compounding. That exposure belongs to your clinic as much as it belongs to the pharmacy.

Research Use Only (RUO) compounds — including certain peptides — occupy a separate regulatory category entirely. RUO products are not intended for clinical administration to patients. They are labeled for research purposes only.

Some providers use RUO compounds in clinical settings. This is a complex area with significant regulatory and liability considerations that go beyond the 503A/503B framework. If you're considering RUO compounds, get specific legal guidance before proceeding.

Ask yourself these questions:

1. Do you have a licensed prescriber issuing patient-specific prescriptions? If yes, 503A is your baseline pathway.
2. Do you need to stock compounded medications in your facility without a prescription in hand? If yes, you need a 503B outsourcing facility.
3. Are you a hospital, ASC, or high-volume institutional provider? 503B is likely required.
4. Are you a telehealth platform prescribing to individual patients? 503A is your pathway.

Most outpatient clinics, med spas, and telehealth providers operate under 503A. The key is making sure your 503A pharmacy is actually operating within 503A law — not cutting corners that expose your practice.

MedClinic Partners works with both 503A and 503B supply channels. Our NPI-verified portal connects licensed providers with the right supply pathway for their practice model — with COAs on every shipment and a compliance team that tracks regulatory changes so you don't have to. Apply for access in under 60 seconds.